Cost-Utility Analysis of Crizotinib as First Line Medication on Late Stage ALK Positive Non-Small Cell Lung Cancer Patients in Taiwan

Cost-Utility Analysis of Crizotinib as First Line Medication on Late Stage ALK Positive Non-Small Cell Lung Cancer Patients in Taiwan

碩士 === 國立臺灣大學 === 健康政策與管理研究所 === 104 === Purpose: This study aimed to estimate the cost-utility of Crizotinib treatment as first-line medication on late stage ALK positive non-small-cell lung cancer patients compare to current chemotherapy from the payer’s perspective in Taiwan. Methods: A cost-uti...

Full description

Bibliographic Details
Main Authors: Kang-Yi Liu, 劉岡易
Other Authors: Ming-Chin Yang
Format: Others
Language:zh-TW
Published: 2016
Online Access:http://ndltd.ncl.edu.tw/handle/30820932153784582551

Similar Items

Similar Items